Semglee has been approved for over a year as a regular biosimilar to Lantus (insulin glargine), meaning that it could be used in place of Sanofi's drug, but only if specifically prescribed for a ...

For instance, the European Medicines Agency (EMA) approved Biocon's insulin glargine biosimilar, Semglee, in September 2023 ...

One company that received approval for an insulin biosimilar in the US is Viatris, for its Semglee (insulin glargine-yfgn) product. In a recent fourth quarter investor call, Sanjeev Narula ...

This approval brings to 37 the number of approved biosimilar products and is the third interchangeable biosimilar to be approved (the others being Semglee (insulin glargine-yfgn) and Cyltezo ...

The company also received the USFDA approval for Semglee, which will enable it to expand patient access to the Insulin Glargine through its partner Mylan. The company also targets to have at least ...